NASDAQ:MESO Mesoblast (MESO) Stock Price, News & Analysis → These AI trades triggered this morning (545% return) (From Prosper Trading Academy) (Ad) Free MESO Stock Alerts $6.24 +0.09 (+1.46%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$6.04▼$6.3650-Day Range$1.97▼$6.5952-Week Range$1.61▼$10.24Volume324,533 shsAverage Volume1.78 million shsMarket Capitalization$711.80 millionP/E RatioN/ADividend YieldN/APrice Target$13.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Mesoblast alerts: Email Address Mesoblast MarketRank™ Stock AnalysisAnalyst RatingHold2.17 Rating ScoreUpside/Downside119.0% Upside$13.67 Price TargetShort InterestHealthy0.63% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.33Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.71) to ($0.60) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.37 out of 5 starsMedical Sector486th out of 913 stocksBiological Products, Except Diagnostic Industry75th out of 146 stocks 3.1 Analyst's Opinion Consensus RatingMesoblast has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 2 buy ratings, 3 hold ratings, and 1 sell rating.Amount of Analyst CoverageMesoblast has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.63% of the outstanding shares of Mesoblast have been sold short.Short Interest Ratio / Days to CoverMesoblast has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Mesoblast has recently decreased by 69.40%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMesoblast does not currently pay a dividend.Dividend GrowthMesoblast does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MESO. Previous Next 2.4 News and Social Media Coverage News SentimentMesoblast has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Mesoblast this week, compared to 2 articles on an average week.Search InterestOnly 17 people have searched for MESO on MarketBeat in the last 30 days. This is a decrease of -26% compared to the previous 30 days.MarketBeat Follows15 people have added Mesoblast to their MarketBeat watchlist in the last 30 days. This is an increase of 1,400% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mesoblast insiders have not sold or bought any company stock.Percentage Held by Insiders18.80% of the stock of Mesoblast is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 1.43% of the stock of Mesoblast is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Mesoblast are expected to grow in the coming year, from ($0.71) to ($0.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mesoblast is -5.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mesoblast is -5.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMesoblast has a P/B Ratio of 1.01. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About Mesoblast Stock (NASDAQ:MESO)Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.Read More MESO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MESO Stock News HeadlinesApril 22, 2024 | americanbankingnews.comGilead Sciences (NASDAQ:GILD) and Mesoblast (NASDAQ:MESO) Critical ContrastApril 16, 2024 | msn.comInsiders are buying Mesoblast and these ASX sharesApril 27, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.April 10, 2024 | seekingalpha.comMesoblast Limited: Back From The DeadApril 5, 2024 | msn.comWhy is everyone talking about Mesoblast shares?April 4, 2024 | finance.yahoo.comSpinal Fusion Pipeline Report 2024, Including Stages of Development, Segments, Region and Countries, Regulatory Path and Key CompaniesApril 3, 2024 | msn.comFed members back cutting rates this year, but need confidence inflation slowingApril 3, 2024 | investorplace.comFeeling Bold? 3 Aggressive Plays to 10X Your Returns by 2025April 27, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.April 3, 2024 | au.investing.comTop ASX Stocks for this MonthApril 2, 2024 | fool.com.auMesoblast share price dumps 10% as excitement simmers on FDA submissionApril 2, 2024 | au.investing.comWhat is next for Tesla stock after soft Q1 sales reportApril 1, 2024 | fool.com.auBlast off! Mesoblast share price surging 60%March 31, 2024 | fool.com.auTop ASX shares to buy in April 2024March 29, 2024 | finance.yahoo.comAohua receives Endoscopy Award at Healthcare Asia Medtech Awards 2024March 28, 2024 | morningstar.comMesoblast Ltd LWBMarch 27, 2024 | afr.comASX retreats ahead of CPI; Mesoblast soars 45pcMarch 27, 2024 | msn.comiBio, ImmunityBio, Mesoblast among healthcare moversMarch 26, 2024 | msn.comFDA Commentary Sends Biotech Soaring During Premarket HoursMarch 26, 2024 | marketwatch.comMesoblast Shares Jump After FDA Nod for Submission of Remestemcel-L ApplicationMarch 26, 2024 | fool.com.auMesoblast share price rockets 36% on breaking FDA newsMarch 26, 2024 | afr.comASX slips as tech declines; Mesoblast soars 47pcMarch 26, 2024 | markets.businessinsider.comFDA Indicates Adequate Data For Mesoblast's Remestemcel-L BLA Submission In Children With SR-aGVHDMarch 25, 2024 | globenewswire.comUnited States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)March 20, 2024 | finance.yahoo.comMESO Jan 2025 0.500 callMarch 19, 2024 | finance.yahoo.comMESO Oct 2024 2.000 callMarch 19, 2024 | finance.yahoo.comMESO Jul 2024 2.000 putSee More Headlines Receive MESO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mesoblast and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/30/2023Today4/27/2024Next Earnings (Estimated)5/23/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:MESO Previous SymbolOTCMKTS:MBLTY CUSIPN/A CIK1345099 Webwww.mesoblast.com Phone(139) 639-6036Fax61-3-9639-6030Employees83Year FoundedN/APrice Target and Rating Average Stock Price Target$13.67 High Stock Price Target$34.00 Low Stock Price Target$3.00 Potential Upside/Downside+119.0%Consensus RatingHold Rating Score (0-4)2.17 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.21 Current Ratio2.71 Quick RatioN/A Sales & Book Value Annual Sales$7.50 million Price / Sales94.91 Cash FlowN/A Price / Cash FlowN/A Book Value$6.16 per share Price / Book1.01Miscellaneous Outstanding Shares114,070,000Free Float92,626,000Market Cap$711.80 million OptionableOptionable Beta3.60 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Silviu Itescu FACP (Age 67)FACRA, FRACP, MBBS (Hons), Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director Comp: $738.74kDr. Eric A. Rose M.D. (Age 73)Chief Medical Officer & Executive Director Comp: $625.46kMr. Andrew Chaponnel B.Com.Interim Chief Finance OfficerMr. Peter T. Howard B.Sc. (Age 56)L.L.B., LLB (Hons), General Counsel & Corporate Executive Mr. Roger D. Brown BAHead of Spinal Orthopedic DisordersMr. Michael Schuster BSc (Age 47)M.B.A., MS, Head of Pharma Partnering Ms. Geraldine Storton B.Sc.M.B.A., MMS, Head of Regulatory Affairs & Quality ManagementMr. Justin Horst B.S.Head of ManufacturingMs. Niva Sivakumar B.Com.L.L.B., Joint Company SecretaryMr. Paul Hughes BPHARMJoint Company SecretaryMore ExecutivesKey CompetitorsCullinan OncologyNASDAQ:CGEMCabaletta BioNASDAQ:CABAHilleVaxNASDAQ:HLVXCARGO TherapeuticsNASDAQ:CRGXRelay TherapeuticsNASDAQ:RLAYView All CompetitorsInstitutional OwnershipPenbrook Management LLCSold 150,175 shares on 4/18/2024Ownership: 0.110%Chapin Davis Inc.Sold 7,000 shares on 4/18/2024Ownership: 0.009%Affinity Asset Advisors LLCSold 400,000 shares on 2/13/2024Ownership: 0.000%View All Institutional Transactions MESO Stock Analysis - Frequently Asked Questions Should I buy or sell Mesoblast stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mesoblast in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MESO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MESO, but not buy additional shares or sell existing shares. View MESO analyst ratings or view top-rated stocks. What is Mesoblast's stock price target for 2024? 6 brokerages have issued 12 month target prices for Mesoblast's shares. Their MESO share price targets range from $3.00 to $34.00. On average, they predict the company's share price to reach $13.67 in the next year. This suggests a possible upside of 119.0% from the stock's current price. View analysts price targets for MESO or view top-rated stocks among Wall Street analysts. How have MESO shares performed in 2024? Mesoblast's stock was trading at $2.20 on January 1st, 2024. Since then, MESO stock has increased by 183.6% and is now trading at $6.24. View the best growth stocks for 2024 here. Are investors shorting Mesoblast? Mesoblast saw a decrease in short interest during the month of April. As of April 15th, there was short interest totaling 716,100 shares, a decrease of 69.4% from the March 31st total of 2,340,000 shares. Based on an average daily volume of 2,160,000 shares, the short-interest ratio is presently 0.3 days. View Mesoblast's Short Interest. When is Mesoblast's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 23rd 2024. View our MESO earnings forecast. How were Mesoblast's earnings last quarter? Mesoblast Limited (NASDAQ:MESO) released its quarterly earnings data on Wednesday, August, 30th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.06. The firm earned $2.14 million during the quarter, compared to the consensus estimate of $2 million. When did Mesoblast's stock split? Shares of Mesoblast reverse split on the morning of Friday, January 5th 2024. The 1-2 reverse split was announced on Friday, January 5th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 50 shares after the split. What other stocks do shareholders of Mesoblast own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mesoblast investors own include Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Exelixis (EXEL), CRISPR Therapeutics (CRSP), Novavax (NVAX), Micron Technology (MU), Vaxart (VXRT) and AbbVie (ABBV). When did Mesoblast IPO? Mesoblast (MESO) raised $69 million in an IPO on Friday, November 13th 2015. The company issued 5,700,000 shares at $12.10 per share. J.P. Morgan and Credit Suisse acted as the underwriters for the IPO and Maxim Group and Ladenburg Thalmann were co-managers. Who are Mesoblast's major shareholders? Mesoblast's stock is owned by many different retail and institutional investors. Top institutional shareholders include Penbrook Management LLC (0.11%) and Chapin Davis Inc. (0.01%). How do I buy shares of Mesoblast? Shares of MESO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MESO) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersA.I. is a Tidal Wave - Here’s What to BuyChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mesoblast Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
